Literature DB >> 15663332

Technology evaluation: lumiliximab, Biogen Idec.

Janice M Reichert1.   

Abstract

Biogen Idec (formerly IDEC Pharmaceuticals) is developing lumiliximab, a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15663332

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  4 in total

Review 1.  Antibody-based therapy of leukaemia.

Authors:  John C Morris; Thomas A Waldmann
Journal:  Expert Rev Mol Med       Date:  2009-09-30       Impact factor: 5.600

Review 2.  Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.

Authors:  Laura S Treml; William J Quinn; John F Treml; Jean L Scholz; Michael P Cancro
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

Review 3.  Omalizumab and IgE in the Control of Severe Allergic Asthma.

Authors:  Yasuhiro Gon; Shuichiro Maruoka; Kenji Mizumura
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

4.  Serum free IgE guided dose reduction of omalizumab: a case report.

Authors:  Yasuhiro Gon; Reiko Ito; Shuichiro Maruoka; Kenji Mizumura; Yutaka Kozu; Hisato Hiranuma; Yuko Iida; Sotaro Shikano; Shu Hashimoto
Journal:  Allergy Asthma Clin Immunol       Date:  2017-08-31       Impact factor: 3.406
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.